Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial

AIMS: Despite the effects of statins in reducing cardiovascular events and slowing progression of coronary atherosclerosis, significant cardiovascular (CV) risk remains. Icosapent ethyl (IPE), a highly purified eicosapentaenoic acid ethyl ester, added to a statin was shown to reduce initial CV event...

Descripción completa

Detalles Bibliográficos
Autores principales: Budoff, Matthew J, Bhatt, Deepak L, Kinninger, April, Lakshmanan, Suvasini, Muhlestein, Joseph B, Le, Viet T, May, Heidi T, Shaikh, Kashif, Shekar, Chandana, Roy, Sion K, Tayek, John, Nelson, John R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Fast Track Congress
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7654934/
https://www.ncbi.nlm.nih.gov/pubmed/32860032
http://dx.doi.org/10.1093/eurheartj/ehaa652

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7654934/
https://www.ncbi.nlm.nih.gov/pubmed/32860032
http://dx.doi.org/10.1093/eurheartj/ehaa652

Ejemplares similares